Please use this identifier to cite or link to this item:
|Title:||Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation||Authors:||Germani, Giacomo
Watt, Kymberly D
|Keywords Plus:||NONALCOHOLIC FATTY LIVER;MAGNETIC-RESONANCE ELASTOGRAPHY;METABOLIC SYNDROME;CARDIOVASCULAR-DISEASE;DIABETES-MELLITUS;HEPATIC STEATOSIS;WEIGHT-GAIN;IMMUNOSUPPRESSIVE REGIMEN;AMERICAN ASSOCIATION;RESISTANCE EXERCISE||Mesh headings:||Consensus Development Conferences as Topic;Liver Cirrhosis;Liver Transplantation;Non-alcoholic Fatty Liver Disease;Secondary Prevention||Secondary Mesh headings:||Allografts;Biopsy;Comorbidity;Humans;Liver;Practice Guidelines as Topic;Recurrence;Risk Factors;Time Factors;Treatment Outcome||Issue Date:||2019||Publisher:||LIPPINCOTT WILLIAMS & WILKINS||Journal:||Transplantation||Abstract:||
Nonalcoholic steatohepatitis (NASH) is a growing indication for liver transplant whether the primary or secondary cause of liver disease, and it is expected to be the leading indication in the years to come. Nonalcoholic steatohepatitis recurs after transplant but the impact of the recurrence on allograft and patient outcomes is unclear. A group of multidisciplinary transplant practice providers convened at the International Liver Transplantation Society NASH consensus conference with the purpose of determining the current knowledge and future directions for understanding the recurrence rates, risk and management of NASH in the transplant allograft. Specific questions relating to posttransplant NASH were proposed and reviewed in detail with recommendations on future actions to fill the knowledge gaps.
|Appears in Collections:||Articles|
Show full item record
checked on Jul 15, 2021
checked on Sep 1, 2020
WEB OF SCIENCETM
checked on Dec 4, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.